Table 1.
Prevalence of anti-SARS-CoV-2 (S1) IgG antibodies among indigenous populations by village
| Population | Age range | Sex | Rapid test results | ELISA IgG anti-spike S1 results | N deaths | |||||||
| Male N (%) |
Female N (%) |
N tested | Negative N (%) |
IgM N (%) |
IgG N (%) |
N tested | Negative N (%) |
Ind N (%) |
IgG N (%) |
|||
| Xikrin do Bacajá7 | 2–84 years | 51 (51.0) | 49 (49.0) | 100 | 42 (42) | nt | 58 (58) | 100 | 27 (27) | 0 (0) | 73 (73) | 01 |
| Asurini | 17–42 years | 0 (0) | 8 (100) | 0 | nt | nt | nt | 08 | 7 (87.5) | 1 (12.5) | 0 (0) | 0 |
| Araweté | 8 months to 84 years | 258 (50.8) | 250 (49.2) | 236 | 29 (12.3) | 11 (4.7) | 196 (83) | 508 | 92 (18.1) | 12 (2.4) | 404 (79.5) | 0 |
| Parakanã | 7 months to 95 years | 106 (50.5) | 104 (49.5) | 195 | 06 (3.1) | 39 (20) | 150 (76.9) | 210 | 65 (30.9) | 06 (2.8) | 139 (66.2) | 01 |
| Munduruku | 7 months to 89 years | 116 (36.6) | 201 (63.4) | 166 | 96 (57.8) | nt | 70 (42.2) | 317 | 139 (43.9) | 14 (4.4) | 164 (51.7) | 05 |
| Kararaô | 1–94 years | 21 (47.7) | 23 (52.3) | 44 | 13 (29.5) | 1 (2.3) | 30 (68.2) | 44 | 9 (20.4) | 0 (0) | 35 (79.5) | 0 |
| Total | 7 months to 95 years | 552 (46.5) | 635 (53.5) | 741 | 185 (25.0) | 51 (6.9) | 505 (68.1) | 1.187 | 339 (28.5) | 33 (2.8) | 815 (68.7) | 07 |
Ind, indeterminate; nt, not tested.